Moshe Talpaz spends much of his time researching Internal medicine, Chronic myelogenous leukemia, Immunology, Gastroenterology and Imatinib mesylate. His Internal medicine research integrates issues from Surgery, Philadelphia chromosome and Oncology. The Chronic myelogenous leukemia study combines topics in areas such as Salvage therapy, Alpha interferon, Bone marrow and Transplantation.
His Immunology study frequently links to related topics such as Clinical significance. His Gastroenterology study integrates concerns from other disciplines, such as Combination chemotherapy, Chemotherapy, Hematologic Response, Pathology and Toxicity. Moshe Talpaz has included themes like Growth factor receptor and Drug resistance in his Imatinib mesylate study.
Moshe Talpaz mainly investigates Internal medicine, Chronic myelogenous leukemia, Immunology, Cancer research and Gastroenterology. Moshe Talpaz combines subjects such as Surgery and Oncology with his study of Internal medicine. His Chronic myelogenous leukemia research is multidisciplinary, incorporating perspectives in Chemotherapy, Alpha interferon, Philadelphia chromosome, breakpoint cluster region and Bone marrow.
His Immunology study combines topics in areas such as Cancer and Haematopoiesis. His research in Cancer research intersects with topics in Tyrosine kinase, ABL, K562 cells and Tyrosine-kinase inhibitor. His work in Gastroenterology tackles topics such as Adverse effect which are related to areas like Discontinuation.
Moshe Talpaz mainly focuses on Internal medicine, Myelofibrosis, Oncology, In patient and Cancer research. His research investigates the connection between Internal medicine and topics such as Gastroenterology that intersect with issues in Tolerability. The concepts of his Myelofibrosis study are interwoven with issues in Clinical trial and Cohort.
His Oncology research incorporates elements of Relapsed refractory, Refractory, Nilotinib and Transplantation. His studies deal with areas such as Apoptosis, Cell culture, Gene knockdown and Cancer as well as Cancer research. His Myeloid leukemia research is multidisciplinary, relying on both Tyrosine kinase, Leukemia, Philadelphia chromosome and Tyrosine-kinase inhibitor.
Moshe Talpaz mostly deals with Internal medicine, Adverse effect, Myelofibrosis, Oncology and Cancer research. His Internal medicine study combines topics in areas such as Gastroenterology and Surgery. Myeloid leukemia is the focus of his Cancer research research.
His biological study spans a wide range of topics, including Tyrosine kinase, Philadelphia chromosome, Tyrosine-kinase inhibitor, Leukemia and Protein kinase domain. His Philadelphia Chromosome Positive research incorporates elements of Nuclear medicine and Immunology. His work on Imatinib mesylate as part of general Imatinib research is frequently linked to EPIC, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Brian J. Druker;Moshe Talpaz;Debra J. Resta;Bin Peng.
The New England Journal of Medicine (2001)
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
Brian J. Druker;Charles L. Sawyers;Hagop M Kantarjian;Debra J. Resta.
The New England Journal of Medicine (2001)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot.
The New England Journal of Medicine (2002)
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
Moshe Talpaz;Neil P. Shah;Hagop M Kantarjian;Nicholas Donato.
The New England Journal of Medicine (2006)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy.
The New England Journal of Medicine (2012)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman.
The biology of chronic myeloid leukemia
Stefan Faderl;Moshe Talpaz;Zeev Estrov;Susan O'Brien.
The New England Journal of Medicine (1999)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman.
The Molecular Genetics of Philadelphia Chromosome–Positive Leukemias
Razelle Kurzrock;Jordan U. Gutterman;Moshe Talpaz.
The New England Journal of Medicine (1988)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre.
The New England Journal of Medicine (2013)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: